Yahsho
4 minutes ago
This is too easy.
CytoDyn’s recent press release on February 24, 2025, dropped two key pieces of news that support the case for their Leronlimab BLA. First, they stated,
“The manuscript for the CD02 Phase 3 study in patients with multidrug-resistant HIV has also just